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By using high-performance liquid chromatography, the in vitro conversion of pentamidine to the corre-
sponding amidoximes (N-hydroxypentamidine and N,N'-dihydroxypentamidine) was studied in supernatants of
rat liver homogenate centrifuged at 9,000 x g. The presence of the two amidoxime peaks in chromatograms was
confirmed by liquid secondary ion mass spectrometry and by unequivocal synthesis of the suspected
metabolites. The metabolic reactions were found to be catalyzed by the cytochrome P-450 system (mixed-
function oxidases). The formation of the monohydroxylated product was found to have a Km of 0.48 mM and
a Vmax of 29.50 pmol/min per mg of protein, while the dihydroxylated metabolite had a Km of 0.73 mM and a
Vmax of 4.10 pmol/min per mg of protein. N,N'-Dihydroxypentamidine was found to have highly reduced
antiprotozoal activity in vitro relative to that of pentamidine, and neither of the hydroxylated metabolites nor
pentamidine was found to be significantly mutagenic by the Ames test. Contrary to previous reports,
pentamidine is readily metabolized to at least two hydroxylated products, and this conversion may be relevant
to the clinical use of the compound and to future drug design.
Pentamidine [1,5-di(4-amidinophenoxy)pentane] was syn-
thesized in the late 1930s and has been used in the prophy-
laxis and treatment of African trypanosomiasis and treat-
ment of antimony-resistant leishmaniasis (24, 32). The
compound was found to be effective against Pneumocystis
carinii pneumonia as early as 1957 (22), but it was not used
extensively to treat P. carinii pneumonia until the acquired
immunodeficiency syndrome epidemic (31). Currently, pen-
tamidine is one of the drugs of choice for the treatment of
acquired immunodeficiency syndrome-related P. carinii
pneumonia (24, 31, 32).
While the pharmacological properties of pentamidine have
been studied for decades (23, 24, 26, 36, 37), the recent
development of sensitive high-performance liquid chromato-
graphic (HPLC) and biological assays has permitted detailed
studies of the distribution and pharmacokinetics of the
compound (1-3, 12, 13, 16, 17, 27). However, there have
been no published attempts to determine the metabolic fate
of pentamidine, largely because of the long-held concept that
the drug is metabolically inert (18, 24, 32). This conclusion is
primarily based on experiments by Launoy et al. (25, 26),
who used pentamidine labeled with 14C in either an amidino
or an aliphatic position. Recent work by Clement and
Zimmermann (5, 9-11) demonstrating that benzamidine is
converted to the corresponding benzamidoxime in superna-
tants of rat liver homogenate centrifuged at 9,000 x g (9,000
x g supernatants) strongly suggested that pentamidine could
undergo a similar metabolic transformation. In this report we
describe the isolation and characterization of two N-hydrox-
ylated metabolites of pentamidine from incubations of the
drug in 9,000 x g rat liver preparations. Four additional
putative metabolites were observed, but they have not yet
been characterized. While several investigators have com-
mented on the possibility of pentamidine metabolism (2, 12,
38), this study constitutes the first identification of any
metabolites of the drug.
* Corresponding author.
MATERIALS AND METHODS
Compounds. Pentamidine isethionate was obtained from
LyphoMed Inc. (Rosemont, Ill.), and the mono- and dioxi-
mes of pentamidine and benzamidoxime were synthesized in
the laboratories of R. R. Tidwell by the method of Tiemann
(35). The structures of the compounds are shown in Fig. 1.
Benzamidine was acquired from Eastman Organic (Roches-
ter, N.Y.). NADPH tetrasodium salt and 1-heptanesulfonic
acid sodium salt were obtained from Sigma Chemical Co.
(St. Louis, Mo.), tetramethylammonium chloride (TMAC)
was obtained from Fluka (Zurich, Switzerland), and aniline
was obtained from Allied Chemical Co. (Morristown, N.J.).
HPLC-grade acetonitrile was acquired from Fisher Scientific
Co. (Fairlawn, N.J.), and all water was deionized and
filtered through a water purification system (Darco, Durham,
N.C.).
Experimental incubations. (i) Preparation of liver homoge-
nates. Barrier-raised male Sprague-Dawley rats (Hilltop
Laboratories, Scottdale, Pa.) were euthanized; and the livers
were removed immediately, rinsed with phosphate buffer
(pH 7.4; 8.7 mM KH2PO4, 30.4 mM Na2HPO4), weighed,
and placed on ice. In a 4°C room, the livers were minced
with scissors and homogenized with approximately 2 vol-
umes of 1.15% KCl (0.154 M) by using a motorized Teflon
(E. I. du Pont de Nemours & Co., Inc., Wilmington, Del.)
pestle glass tube homogenizer (A. H. Thomas Co., Philadel-
phia, Pa.). The homogenates were transferred to polycar-
bonate tubes and centrifuged at 9,000 x g for 30 min in a
centrifuge (RC-2B; Ivan Sorvall, Inc., Norwalk, Conn.)
equipped with a GSA rotor. The supernatant was carefully
decanted and used as the source of enzyme activity. The
protein content in the supernatant was determined by the
method of Lowry et al. (28). Microsomes were prepared by
centrifuging the 9,000 x g supernatant at 105,000 x g for 60
min in an ultracentrifuge (L3-50; Beckman Instruments,
Inc., Fullerton, Calif.) with a type 40 rotor. The pelleted
microsomes were suspended in phosphate buffer by using
the tissue homogenizer.
1678















FIG. 1. Structures of the compounds examined in this study. (A)
Pentamidine; (B) monooxime of pentamidine (N-hydroxypentami-
dine); (C) dioxime of pentamidine (N,N'-dihydroxypentamidine).
(ii) Incubation conditions. Two sets of incubations were
carried out under similar conditions. For the first experi-
ment, 1.0 ml of liver supernatant and 1.0 ml of cofactor
solution (2.0 mg of NADPH and 1.9 mg of MgCl2) were
added to 3.0 ml of phosphate buffer (pH 7.4) in duplicate
50-ml Erlenmeyer flasks at 37°C in a shaking water bath. One
milliliter of pentamidine isethionate (2.5 mM stock solution
in phosphate buffer) was added to each flask to start the
incubation. Incubations of individual samples were stopped
every 15 min from 0 to 120 min by placing them on ice. The
samples were then stored at -70°C until extraction and
analysis.
The second experiment was identical to the first one,
except that the incubation time of all duplicate samples was
30 min and pentamidine was added to give the following final
concentrations: 8.3, 16.7, 83.3, 166.7, 333.3, 500.0, 666.7,
and 833.3 ,uM. Control incubations of 30 min each were
performed on samples containing an extra 1.0 ml of phos-
phate buffer (pH 7.4) in place of 833.3 p.M pentamidine, liver
supernatant, or cofactor solution.
Microsomal incubations were performed as described
above for the 9,000 x g supernatant incubations, except that
the cofactor mixture contained 2 mg of NADPH per ml, 1.9
mg of MgCl2 per ml, 5 mM glucose-6-phosphate, 0.7 mg of
NADP per ml, and 0.1 U of glucose-6-phosphate-dehydro-
genase per ml.
(iii) Confirmation of enzyme activity. The presence of
mixed-function oxidase enzyme activity was confirmed by
measuring aniline hydroxylase activity as described by Imai
et al. (21). Briefly, 1.0 ml of 10 mM aniline instead of
pentamidine was added to an incubation mixture and was
shaken at 37°C for 30 min. The incubation was stopped by
adding 1.67 ml of 0.3 M ZnSO4-0.3 N Ba(OH)2 to the
incubation mixture and centrifuging the mixture at 1,500 x g
for 5 min in a clinical centrifuge. One milliliter of supernatant
was mixed with 1.5 ml of 5% Na2CO3-0.2 N NaOH-4%
phenol and incubated at 37°C for 30 min, with the subsequent
color being measured at 630 nm in a spectrophotometer.
HPLC assay. Individual incubation samples were ex-
tracted over solid-phase columns (Prep-Sep C-18; Fisher
Scientific Co.) as described previously (1). Samples were
added under gentle vacuum conditions and eluted with 1.0
ml of 95% CH3CN-10 mM heptanesulfonate-10 mM TMAC-
4.2 mM H3PO4 in H20. The eluates were then brought to
dryness under a gentle air stream and suspended in 200 ,ul of
elution buffer for HPLC analysis.
A liquid chromatograph (model 1084B; Hewlett-Packard
Co., Palo Alto, Calif.) equipped with a reporting integrator
(model 79850B; Hewlett-Packard Co., J3oblingen, Federal
Republic of Germany) was used for all analyses. We used a
reverse-phase diisopropyl C-8 column (25 cm by 4.6 mm;
particle size, S ,um; Zorbax RX; Dupont Co.) that was kept
at 40°C. The matrix (RX) was manufactured to be effective
for highly basic compounds and was used when the standard
octadecylsilane C-18 column (Zorbax ODS; Du Pont) used in
previous studies failed to resolve pentamidine and the oxime
standards. The mobile phase was CH3CN-10 mM heptane-
sulfonate-10 mM TMAC-4.2 mM H3P04 in H20 with a
linear 22.5 to 45% CH3CN gradient over 25 min. A 25-pA
portion of each sample was injected, and detection was
performed with a variable-wavelength ultraviolet spectro-
photometer (model 79875A; Hewlett-Packard Co.) set at 265
nm with 540 nm as a reference wavelength.
Standard curves for the mono- and dioximes of pentami-
dine were constructed by adding the standard compound
(93.5 ng to 9.35 ,ug for the monooxime and 49 to 980 ng for
the dioxime) to incubation mixtures of liver homogenates, in
which 1.0 ml of phosphate buffer was added in place of the
cofactor solution. These samples were then immediately
extracted and analyzed as described above. The peak areas
were plotted against the amounts that were added to give a
standard curve. The r2 values were 0.99 for the monooxime
curve and 0.98 for the dioxime curve.
Mass spectrometry. A large-scale incubation was set up by
using 500 mg of pentamidine isethionate in 400 ml of phos-
phate buffer (pH 7.4) containing 50 ml of cofactor solution
(50 mg of NADPH, 47.5 mg of MgCl2 in phosphate buffer)
and 80 ml of the 9,000 x g liver homogenate supernatant.
The incubation was carried out for 6 h at 37°C in a shaking
water bath. Half of this sample was stored at -70°C, and the
other half was extracted over C-18 solid-phase extraction
columns as previously described. A total of 32 ml of column
eluate was dried to approximately 500,ul under a gentle air
stream. Standards were prepared by dissolving several crys-
tals of each standard oxime in 1.5 ml of 95% CH3CN-10 mM
heptanesulfonate-10 mM TMAC-4.2 mM H3P04 in H20.
Mass spectra were obtained by using a tandem hybrid
mass spectrometry-mass spectrometry system (VG 70-250
SEQ; VG, Manchester, United Kingdom) operated in the
liquid secondary ion mass spectrometry (LSIMS) mode.
Samples were introduced via direct probe by using glycerol
as the matrix, a Cs ion gun set at 35 kV, and an 8-kV source
potential. Argon was used as the collision gas in an Rf-only
collision cell, with the collision energy set at 4 to 7 eV
(laboratory reference). Data were acquired by using multi-
channel acquisition and were not centroided.
Mutagenicity assay. The mutagenic potential of pentami-
dine, N-hydroxypentamidine, N,N'-dihydroxypentamidine,
benzamidine, benzamidoxime, and a 30-min incubation of
1.25 mg of pentamidine per ml in 9,000 x g liver homogenate
supernatant (with cofactors) was measured by the method of
Maron and Ames (29). Various amounts of individual com-
pounds were suspended in 10% dimethyl sulfoxide, and 0.1
ml was added to 0.1 ml of Salmonella typhimurium TA100
(hisG428 rfa &uvrB; grown to 108 cells per ml) and 0.5 ml of
phosphate buffer (pH 7.4). Two milliliters of top agar at 45°C
(0.55% agar, 0.46% NaCl, 45,uM L-histidine, 45,uM biotin)
was added, mixed, and poured onto agar plates [30 ml of
1.5% agar, 2% glucose, 0.6% MgSO4. 7H20, 6% citric acid,




were incubated for 48 h at 37°C, and the His' revertants
were enumerated. Control plates that lacked any amidine,
amidoxime, or 9,000 x g liver homogenate supematant were
also incubated.
Antiprotozoal activity of N,N'-dihydroxypentamidine. (i)
Antigiardial assay. The assay for the activity of the dioxime
in vitro was performed as described by Boreham et al. (4).
Serial dilutions of N,N'-dihydroxypentamidine were added
to a 96-well micro-dilution plate; then, 2.5 x 104 organisms
of logarithmically growing Giardia lamblia WB (ATCC
30957) trophozoites in a modified Keister medium containing
5% fetal bovine serum were added to each well. The plate
was then placed in an anaerobic chamber and incubated at
37°C under nitrogen. After 24 h, 1.5 to 2.0 ,uCi of [3H]
thymidine was added to each well. Eighteen hours later, the
cells were harvested onto glass microfiber filters, dried, and
analyzed in a scintillation counter to measure [3H]thymidine
incorporation. Data on the uptake of radiolabeled thymidine
were fitted to a logistic-logarithmic concentration response
function by a nonlinear regression method using a non-
weighted least-squares criterion (15, 30). The concentration
of drug necessary to inhibit 50% incorporation of the labeled
substrate was calculated.
(ii) Antileishmanial assay. The activity of N,N'-dihydroxy-
pentamidine against Leishmania mexicana amazonensis
clone WR669C45 was determined as described in Grogl et al.
(19). Serial dilutions of the drug were added to a 96-well
microdilution plate; then, 1.0 x 106 promastigotes in 200 RI
of Schneider drosophila medium containing 10% heat-inac-
tivated fetal bovine serum were added to each well. The
plate was incubated in air at 25°C for 24 h before the addi-
tion of 1.0 to 2.0 ,uCi of [3H]thymidine per well. After an
additional 18 h of incubation, the cells were harvested,
incorporation was determined, and data were analyzed as
described above.
(iii) Antiplasmodial assay. The activity of N,N'-dihydroxy-
pentamidine against Plasmodium falciparum clones W2
(chloroquine resistant, mefloquine susceptible; Indochina
III/CDC) and D6 (chloroquine susceptible, mefloquine resis-
tant; Sierra Leone I/CDC) was determined by the method of
Oduola et al. (30). Serial dilutions of the drug were added to
a 96-well micro-dilution plate; then, 200 p.d of RPMI 1640
medium containing human type A-positive erythrocytes at a
parasitemia level of 0.2% and a hematocrit level of 1.5% was
added. The plate was incubated at 37°C for 24 h in 5% 0275%
C02-90% N2, before the addition of 1.0 to 2.0 ,uCi of
[3H]hypoxanthine per well. After an additional 18 h of
incubation, the cells were harvested, incorporation was
measured, and data were analyzed as described above.
(iv) DNA-binding activity. The DNA binding of N,N'-
dihydroxypentamidine and pentamidine was measured by
the method of Cory et al. (14). Sonicated calf thymus DNA
was added to either compound at a 1:10 drug to base ratio,
and the change in the midpoint of the thermal denaturation
curve (ATm) was measured under low ionic conditions.
RESULTS
Pentamidine incubations. Standard samples of pentami-
dine, monooxime, and dioxime were analyzed by HPLC to
determine the relative retention times of the compounds.
Pentamidine was found to have a retention time of approx-
imately 12.5 min, while those of the mono- and dioximes of
pentamidine were found to be approximately 11.9 and 11.6
min, respectively (Fig. 2). The aniline hydroxylase activity
of the liver preparation was 0.54 ± 0.09 nmol converted per
CbaN
0 10 0is2
FIG. 2. Chromatogram of standard pentamidine and the corre-
sponding amidoximes. Separation was performed with a diisopropyl
C-8 column (Zorbax RX) with 22.5 to 45% CH3CN-10 mM heptane-
sulfonate-10 mM TMAC-4.2 mM H3PO4 in H20 graded over 25 min
(as described in the text). Pentamidine had a retention time of 12.5
min (peak a), the monooxime had a retention time of 11.9 min (peak
b), and the dioxime had a retention time of 11.6 min (peak c).
min per mg of protein, which demonstrates that microsomal
enzymes were both present and active.
Control incubations were set up in which pentamidine,
cofactor solution, or the 9,000 x g liver homogenate super-
natant was excluded from the normal 30-min incubation
mixture. When the 9,000 x g liver homogenate supernatant
or cofactor was excluded, only very small peaks could be
detected in the region of interest, and no peaks were
detected when pentamidine was excluded. (Fig. 3). In the
experimental incubations, when 41.7 puM pentamidine was
present in the 9,000 x g liver homogenate. supernatant
preparation with cofactor solution, peaks which coeluted
with the mono- and dioximes could be. detected by HPLC in
the sample at 15 min and increased in concentration with
each subsequent sample obtained every 15 min (data not
shown). Chromatograms of the samples obtained at 15 and
105 min are shown in Fig. 4. It is of interest to note that while
the two oximes were present in the incubations, there were
four other peaks that were not present in the control incu-
bations (Fig. 4, peaks c, d, e, and f).
To determine the enzyme(s) in the 9,000 x g supernatant
that was responsible for the metabolism of pentamidine, a
series of incubations was performed with both 9,000 x g rat
liver homogenate supernatants and. microsomes isolated
from these supernatants (Table 1). All putative metabolites
were detected in both 9,000 x g supernatants with cofactor
and microsomes with cofactor, but not in the 105,000 x g
supernatant (supplied with the microsomal cofactor). Addi-
tionally, the addition of carbon monoxide or the cytochrome
P450-inactivating agent SKF-525A to microsomal incuba-
tions prevented the metabolism of pentamidine. These re-
sults indicate that the cytochromes P-450 (mixed-function
oxidases) are responsible for the. metabolism of pentamidine.
Kinetics of oxime production. To determine the enzymatic
kinetics of production of the oximes of pentamidine, 30-min
incubations were performed by using concentrations of
pentamidine that ranged from 8.3 to 833.3 p.M. The samples
were extracted and analyzed by HPLC, and the peak areas
were converted to nanomoles by using standard curves.
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FIG. 3. Chromatograms of control liver homogenate incuba-
tions. Thirty-minute incubations were performed at 37°C by using
3.0 ml of phosphate buffer, 1.0 ml of the 9,000 x g liver homogenate
supernatant, 1.0 ml of cofactor solution (2.0 mg of NADPH and 1.9
mg of MgCl2), and 833.3 ,M pentamidine. (A) Liver supernatant
was not included; (B) cofactor solution was not included; (C)
pentamidine was not included. Samples were extracted and chro-
matograpbed as described in the text.
Lineweaver-Burk plots were then constructed for both the
mono- and dioximes (Fig. 5). The monooxime of pentami-
dine was found to have a Km of 0.48 mM and a Vmax of 29.50
pmol/min per mg of protein, while the dioxime was found to
have a K-m of 0.73 mM and a Vmax of 4.10 pmollmin per mg
of protein. Incubation with 833.3 ,uM pentamidine was not
A
TABLE 1. Incubation of pentamidine with fractions of
rat liver homogenatesa
Detection of the following
metabolite peaks by
Sample HPLCb:
a b c d e f
9,000 x g supernatant with cofactor + + + + + +
9,000 x g supernatant without cofactor - - - - - -
105,000 x g supernatant with cofactor
Microsomes with cofactor + + + + + +
Microsomes without cofactor
Microsomes with cofactor and 100%
carbon monoxide
Microsomes with cofactor and 0.83 mM
SKF-525A
a Pentamidine (final concentration, 0.167 mM) was incubated with 1.0 ml of
the indicated fractions of rat liver homogenates. All incubations were per-
formed at 37°C for 30 min. The samples were then extracted and analyzed as
outlined in the text. Peaks a through f indicate putative metabolite peaks as
labeled in Fig. 4.
b-+, A particular peak was detected by HPLC analysis of a particular
sample; -, the peak was not detected.
included in the kinetic plots because of problems with drug
solubility at-that concentration.
Mass spectrometry. To confirm the results obtained by
HPLC, it was necessary to detect the presence of the two
oximes of pentamidine by mass spectrometry. Standard
mass spectra were obtained by performing LSIMS on the
synthesized oxime standards diluted in the same matrix as
the experimental sample (C-18 elution buffer). Since the
background level from the ion pair agents in the buffer was
high, it was necessary to use mass spectrometry-mass spec-
trometry. The ion corresponding to the known molecular
weight of the standard compound was selected for secondary
fragmentation (the monooxime had an M+ 1 ion of 357, and
the dioxime had an M+ 1 ion of 373). The spectra of the
standard compounds are shown in Fig. 6. The experimental
sample was a larger-scale liver incubation that was extracted
over C-18 columns and concentrated 64-fold. LSIMS mass
spectrometry-mass spectrometry was performed on this
sample by again focusing on the monooxime M+ 1 ion of 357
and the dioxime M+1 ion of 373. The secondary mass
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FIG. 4. Chromatograms of experimental liver homogenate incu-
bations. The incubations were performed at 37°C by using 3.0 ml of
phosphate buffer, 1.0 ml of the 9,000 x g liver homogenate super-
natant, 1.0 ml of cofactor solution (2.0 mg of NADPH and 1.9 mg of
MgCl2), and 41.7 p.M pentamidine. (A) Incubation was terminated
after 15 min; (B) incubation was terminated after 105 min. Peak a,
monooxime; peak b, dioxime; peaks c through f, unknown putative
metabolites. Extraction and chromatography of samples were de-
scribed in the text.
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FIG. 5. Lineweaver-Burk plots of the formation of pentamidox-
ime from pentamidine during a rat liver homogenate incubation. (A)
Production of N-hydroxypentamidine over the course of a 30-min
rat liver homogenate incubation. (B) Production of N,N'-dihydrox-
ypentamidine over the course of a 30-min incubation. The final
concentration of pentamidine was 8.3 to 666.7 ,uM; however, no
N,N'-dihydroxypentamidoxime was detected in incubations with
less than 166.7 puM pentamidine. See the text for more details and
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FIG. 6. Secondary mass spectra of the mono- and diamidoximes of pentamidine from standards and experimental incubations. LSIMS
mass spectrometry-mass spectrometry was performed by direct-probe bombardment of the sample with cesium ions to produce molecular
ions. The molecular ion corresponding to the compound of interest was then selected for secondary fragmentation by collision with argon gas.
These secondary fragments are shown for the ion at 357 from a liver homogenate incubation of pentamidine (A), the ion at 373 from the same
liver homogenate incubation (B), standard monooxime (M+ 1 = 357) (C), and standard dioxime (M+ 1 = 373) (D). Incubation and extraction
conditions are outlined in the text. Each spectrum is displayed as percent intensity (I) against mass/charge ratio.
sample are shown in Fig. 6 with the standard spectra. The
number and intensity of fragment peaks matched well, thus
confirming the presence of the mono- and dioximes of
pentamidine in the 9,000 x g liver homogenate preparation
incubations.
Mutagenicity. Several concentrations of pentamidine,
N-hydroxypentamidine, N,N'-dihydroxypentamidine, benz-
amidine, benzamidoxime, or 9,000 x g liver homogenate
supernatant incubation of 1.25 mg of pentamidine per ml
were analyzed for mutagenicity by the test of Maron and
Ames (29). Induction of His' revertants of S. typhimurium
TA100 measured the relative mutagenicity of each of the
compounds (Table 2). None of the compounds tested ap-
peared to be strongly mutagenic, but the 30-min liver super-
natant incubation of pentamidine was more mutagenic than
any of the five drugs at all doses higher than 0.1 ,ug per plate.
Pentamidine appeared to be toxic to the cells at doses higher
than 2.5 ,ug per plate, and N-hydroxypentamidine appeared
to be toxic at doses higher than 0.1 ,ug per plate. While
neither benzamidine nor benzamidoxime was highly muta-
genic, benzamidoxime appeared to be more genotoxic than
benzamidine, confirming the results of Clement et al. (7). It
is clear from the data in Table 2 that neither N-hydroxypen-
tamidine nor N,N'-dihydroxypentamidine is more mutagenic
than pentamidine.
Antiprotozoal activity. N,N'-Dihydroxypentamidine was
tested in vitro for activity against G. lamblia, L. mexicana
amazonensis, and two strains of P. falciparum (W2, chloro-
quine resistant, mefloquine susceptible; D6, chloroquine
susceptible, mefloquine resistant). The drug was tested from
1.372 to 1,000 ,uM against G. lamblia, from 0.137 to 100 ,uM
TABLE 2. Mutagenic activity of amidines and amidoximes
in S. typhimuriuma
No. of His' revertants of S. typhimuriuml
plate (minus control value) with the
Treatment following concn (>m) of drug/plate':
100 10 5 2.5 1 0.1
Pentamidine 0 0 0 45 43.5 37.5
Pentamidine in 6-h liver 46 74 74 65.5 69.5 13.5
incubation
N-Hydroxypentamidine 3.5 0 0 0 0 14.5
N-N'-Dihydroxypentamidine 19 13.5 25 7 24.5 0
Benzamidine 15 24 11 1.5 26 13.5
N-Hydroxybenzamidine 27.5 41 33.5 15.5 20 65
a Various amounts of the indicated compounds or a 6-h incubation of
pentamidine in 9,000 x g rat liver homogenate supernatant were added to 106
S. typhimurium TA100 (His-) cells and plated as described in the text. After
incubation for 48 h at 37'C, the resulting colonies (His' revertants) were
enumerated (29).
6 All drug concentrations were tested on duplicate plates. The control His'
revertant value was 367 ± 18.7.
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against L. mexicana amazonensis, and from 0.001 to 0.1 ,uM
against both strains of P. falciparum. Under these condi-
tions, N,N'-dihydroxypentamidine had no activity. By con-
trast, the concentrations of pentamidine necessary to inhibit
50% incorporation of the labeled substrate were 21.24 ,uM
against G. lamblia, 0.79 ,uM against L. mexicana amazon-
ensis, 0.12 ,uM against P. falciparum W2, and 0.06 ,uM
against P. falciparum D6 (R. R. Tidwell, S. K. Jones, J. D.
Geratz, K. A. Ohemeng, C. A. Bell, B. J. Berger, and J. E.
Hall, Ann. N.Y. Acad. Sci., in press). The lack of activity
displayed by the dioxime indicates that the N-hydroxylation
of pentamidine results in a loss of in vitro antiprotozoal
activity.
A proposed mode of action for the antiprotozoal activity
of pentamidine is by its strong DNA-binding property (14).
The ability of the N,N'-dihydroxy metabolite to bind DNA
similarly was investigated by determining the effect of the
drug on the thermal denaturation curve of sonicated calf
thymus DNA. N,N'-dihydroxypentamidine was found to
have a ATm of 0.2°C. In comparison, pentamidine was found
to have a ATTm of 10.7°C. Therefore, the N-hydroxylation of
pentamidine results in a corresponding loss of almost all the
DNA-binding ability of the parent compound.
DISCUSSION
The long-held conception that pentamidine is not metab-
olized (18, 24, 32) appears to have originated from work
reported in 1960 by Launoy et al. (25, 26). Approximately
80% of the radiolabel was recovered from the urine of rats
and mice injected with ['4C]pentamidine (labeled in either
the amidino moiety or the terminal carbons of the aliphatic
chain). While the results demonstrate that pentamidine is not
metabolically degraded with the subsequent loss of carbon
atoms, they do not address the possibility of nondegradative
metabolism. The results of our study show that pentamidine
can be readily metabolized in vitro by rat liver preparations
and that two of the six putative metabolites detected by
HPLC were found to be N-hydroxypentamidine and N,N'-
dihydroxypentamidine.
Further studies are being performed to determine the
identities of all the remaining pentamidine metabolites and to
investigate metabolism in vivo. Several possibilities for the
structures of the remaining pentamidine metabolites exist
(such as chain or ring hydroxylations), and these compounds
are being synthesized. HPLC analysis of urine from a rat
given a daily dose of 10 mg of pentamidine per kg per day for
14 days showed that several of the putative metabolites were
detected in urine on day 14, but neither of the N-hydroxy
metabolites was detected (data not shown). Similar analyses
of urine from patients with acquired immunodeficiency syn-
drome being treated with pentamidine have been inconclu-
sive because of a lack of proper control samples. Complete
elucidation of the in vitro and in vivo metabolism is under
way with [14C]pentamidine.
Of obvious medical importance are the efficacy and tox-
icity profiles of any pentamidine metabolites relative to those
of the parent compound. The relative mutagenicities of
N-hydroxypentamidine, N,N'-dihydroxypentamidine, and
pentamidine were determined by using the test of Maron and
Ames (29). Neither pentamidine nor the two pentamidoxi-
mes were found to be highly mutagenic. The 9,000 x g liver
homogenate supematant incubation of 1.25 mg of pentami-
dine per ml was found to be more mutagenic than pentami-
dine alone was, suggesting that one or more of the uniden-
tified putative metabolites may be more mutagenic than
pentamidine.
The two pentamidoximes have been synthesized previ-
ously and tested in vivo against African trypanosomal and
leishmanial infections (6). In all cases, it was found that the
amidoximes were active, but they were less active then
pentamidine. However, we determined that N,N'-dihydroxy-
pentamidine displays highly reduced antiprotozoal activity
in vitro when compared with that of pentamidine. In fact, the
activity of the diamidoxime in vitro against all the organisms
tested was so low that the concentration necessary to inhibit
50% incorporation of the labeled substrate could not be
calculated for the compound. It is likely that the difference
seen between in vivo and in vitro activity is due to the
occurrence of the reverse reaction (amidoxime to amidine) in
vivo. This reaction has been demonstrated previously (8, 20)
and could convert enough of the pentamidoxime to penta-
midine to produce the low levels of activity seen in vivo.
Additionally, N,N'-dihydroxypentamidine was found to
have no significant DNA-binding ability (,ATm, 0.2°C). Since
the strong DNA binding of pentamidine (ATm, 10.7°C) is a
postulated mode of action for the drug, this result may
explain the relative inactivity of the amidoxime. The N-hy-
droxylation pathway of pentamidine appears to cause a
significant loss of antiprotozoal activity and, therefore, may
be of consequence in the treatment of P. carinii pneumonia.
The full impact of metabolism on the biological activity of
pentamidine will not be known until all metabolites have
been identified, characterized, and tested for antiprotozoal
activity.
The observation that pentamidine is readily metabolized
requires reexamination of current pentamidine detection
methods. Our previous HPLC method for detecting penta-
midine is inadequate for detecting any of the putative metab-
olites. A comparatively less acidic reversed-phase column is
effective in separating both the parent diamidine and its
corresponding amidoximes (33). HPLC methods for the
detection of pentamidine used by other investigators operate
on principles similar to those of our original procedure (16,
27) and should be subject to the same problems. The
chemical detection method used by several investigators (24,
36, 37) is based on the conversion of pentamidine to a
fluorogenic compound with glyoxal and benzaldehyde, and
the bioassay used by Bernard et al. (3) is based on the ability
of pentamidine to inhibit Candida tropicalis ATCC 28707
growth. While it is likely that the pentamidoximes would not
react in either of these assays, it is not possible to predict the
reactivities of the putative metabolites. Therefore, it is
difficult to assess the effectiveness of these two assays in the
pharmacokinetic study of pentamidine.
With respect to future antimicrobial drug development, it
will be necessary to design analogs of pentamidine with
consideration of the metabolic fate of the drug. Several novel
pentamidine analogs with increased anti-P. carinii activity
and lowered toxicity have been synthesized in our laborato-
ries (34), and the relationship between these properties and
metabolism must be thoroughly investigated. Only when the
metabolic fate of pentamidine is fully determined will it be
possible to fully characterize the pharmacology of the com-
pound and begin a logical search for safer, more effective
anti-P. carinii agents.
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